Humana Inc (HUM) Stock Price Today
Aura AI Summary
Key Stats
- $46.49BMarket Cap
- 2,567,704Volume
- HealthSector
- $409.8552W High
- $163.6752W Low
- 51 DaysTypical Hold Time
- $53.84BEnterprise Value
- 0.91%Div Yield
- 7% Sell | 93% BuyTrading Activity
Track Humana Inc (HUM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Humana Inc has traded between a low of $163.67 and a high of $431.03, highlighting its annual price range. Buy and sell Humana Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Most Recent News
ZenaTech launches AI-powered smart safety glasses Stacklens for field technicians, with pilots in 2027.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...
Class action lawsuit filed over Compass-Anywhere merger alleging regulatory misrepresentation.
The Rosen Law Firm has filed a class action lawsuit on behalf of former Anywhere Real Estate shareholders who received Compass, Inc. stock in a January 2026 merger. The suit alleges that Compass and its executives misrepresented their efforts to secu...
New data supports Furoscix ReadyFlow autoinjector for outpatient edema management in heart failure and CKD.
MannKind presented new clinical data at HFSA 2026 showing that Furoscix ReadyFlow, an autoinjector delivering subcutaneous furosemide, provides diuretic effects comparable to IV administration for treating edema in heart failure and chronic kidney di...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.